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The early assessment of outcomes issuing from reperfusion 
therapy can be clinically elusive (1). Bedside estimates of 
infarct-related coronary artery patency are notoriously inaccu- 
rate even with additional aids, including traditional electrocar- 
diography and conventional e ectrocardiographic (ECG) mon- 
itoring (2,3). Creatine kinase isoforms have been tested as a 
"CK chronometer," heralding reperfusion with apparent suc- 
cess (4-6). Other circulating proteins have been similarly 
studied (7,8). Alas, these techniques have not gained much 
favor nor have they been sufficiently tested to the point where 
they dependably identify infarct-related artery patency (9). 
Given the well appreciated awareness of postreperfusion dy- 
namics of infarct-related artery patency, with its associated 
thrombus/vasomotion-driven variations in blood flow after 
reperfusion has been achieved, we too often find ourselves at 
the mercy of this pathophysiologic mischief in managing acute 
ischemic syndromes. 
What if we could reliably identify the adequate restoration 
of flow in a culprit coronary artery or, perhaps even more 
important, recurrent narrowing of this vessel after reperfu- 
sion? The consequences of reocclusion after thrombolytic 
therapy are potentially disastrous (10). Thus, the Thrombolysis 
and Angioplasty in Myocardial Infarction (TAMI) trialists (11) 
have shown that reocclusion more than doubles early in- 
hospital mortality rates in patients with myocardial infarction 
treated with thrombolytic therapy. A number of studies have 
suggested that adjunctive balloon angioplasty performed se- 
quentially after an inaugural attempt at reperfusion using 
thrombolytic therapy adds little to the eventual early outcome 
of patients with acute myocardial infarction, as shown by the 
results of the TAMI-I (12), Thrombolysis in Myocardial In- 
farction (TIMI)-IIA (13) and TIMI-IIB (14) trials; the Fifth 
European Cooperative Study Group trial (15); the SWIFT 
(Should We Intervene Following Thrombolysis) trial (16); and, 
most recently, by our own institution (17). Moreover, failure of 
immediate angioplasty for failed thrombolysis can be cata- 
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strophic, as first suggested in the TAMI-I trial (18), where the 
mortality rate in this circumstance was fully 44% compared 
with a 6% mortality rate in the patients in this same study with 
insignificant residual stenosis after angioplasty and a 14% 
mortality rate in those with >50% postangioplasty residual 
stenosis. Others (19) have also noted the extremely high 
mortality when angioplasty used for failed thrombolysis has 
proved to be unsuccessful. Nevertheless, although coronary 
angioplasty may be debatably unnecessary (20-22), and per- 
haps even harmful, after thrombolytic treatment of acute 
myocardial infarction, especially if reperfusion has been suc- 
cessful, the clinical benefit of angioplasty for failed thrombol- 
ysis has only recently been examined in a randomized clinical 
trial (23). Heretofore, many physicians took the position that it 
is unethical to withhold rescue angioplasty when unsuccessful 
reperfusion by other strategies i suspected, as is the case in 
20% to 25% of patients treated with thrombolytic agents (24). 
The recently completed Randomized Evaluation of Sal- 
vage Angioplasty With Combined Utilization of Endpoints 
(RESCUE) trial (23) tested the hypothesis that early balloon 
angioplasty inpatients with failed thrombolysis would improve 
clinical outcome within the first month of myocardial infarc- 
tion compared with conservative management alone. Patients 
(n = 151) with a first anterior wall infarction in whom a 
thrombolytic regimen was initially used, and who were subse- 
quently shown angiographically to have an occluded infarct- 
related artery within 8 h of the onset of chest pain, were 
randomized to rescue balloon angioplasty supplemented by 
further thrombolytic therapy as needed or to a conservative 
arm consisting of aspirin, heparin and coronary vasodilators. 
Angioplasty was successful in 72 (92%) of 78 patients in whom 
30-day exercise jection fraction was shown to be significantly 
higher than in patients in the conservative arm (43 _-. 15% vs. 
38 _+ 13%, p = 0.04), although there was no significant 
difference at rest. The combined end points of death and 
severe heart failure were less frequent in the angioplasty group 
(6% vs. 17%, p = 0.05). 
The TAMI-5 trial (3 × 2 factorial design) randomized 
patients to receive recombinant tissue-type plasminogen acti- 
vator (n = 191), urokinase (n = 190) or both lytic agents (n = 
194) (25). Patients were secondarily randomized to two cath- 
eterization strategies: immediate, with angioplasty for failed 
thrombolysis (n = 287), or predischarge catheterization ( = 
288). The aggressive catheterization strategy ielded a higher 
predischarge patency rate (94%) than was observed with the 
conservative strategy (90%, p = 0.065). Regional wall motion 
was better with the aggressive strategy. Using a composite 
clinical end point (death, stroke, reinfarction, reocclusion, 
heart failure or recurrent ischemia) there were more patients 
free of adverse clinical outcomes in the aggressive arm (67%) 
than in the conservative arm (55%, p = 0.004). 
The upshot of these investigations i that in certain circum- 
stances, angioplasty sequential to thrombolysis a legitimate 
consideration. Certainly, this treatment should be considered 
in patients with myocardial infarction and complicating hypo- 
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tension, congestive failure, acute subhisian conduction effects 
or malignant ventricular arrhythmias. If we assume that these 
events are the result of infarct-related artery reocclusion, then 
a simple bedside diagnostic strategy enabling its immediate 
detection would be invaluable. Although adverse ischemic 
events are more likely to complicate primary thrombolysis than 
primary angioplasty for myocardial infarction, the Primary 
Angioplasty in Myocardial Infarction (PAMI) trial (26) has 
shown that the latter strategy isnot free of such complications. 
Accordingly, a method to detect acute reocclusion i  the latter 
instance would be equally valuable. 
From the foregoing it is clear that dynamic assessment of
infarct-related artery patency is something more than an 
exercise in diagnostic acumen in the management of acute 
myocardial infarction. From the standpoint of both salvage and 
rescue, immediate determination of reperfusion outcomes, 
however achieved, is now clinically essential. Real-time iden- 
tification thereof using ECG analysis has been attempted 
throughout the past decade, and considerable progress has 
been achieved at Georgetown University by Krucoff et al. (27) 
utilizing Holter recordings during intracoronary streptokinase 
infusion and for 48 h thereafter. Krucoff et al. found this 
method to be sensitive and specific for assessing coronary 
artery patency during the acute phase of myocardial infarction. 
Subsequent work (28) with three-channel recordings provided 
ST segment "fingerprints" during occlusive balloon angioplasty 
that were used to validate interpretation of early ST segment 
shifts in acute myocardial infarction. Since then, numerous 
studies both here and abroad, only a few of which are 
referenced here (29-35), have attested to the diagnostic 
accuracy and prognostic importance of real-time ST segment 
analysis in assessing the outcome of myocardial reperfusion. 
More recent ECG analysis (36) focusing on the ST segment 
has used a 12-lead array with computerized scaler and digitized 
three-dimensional displays of ST segment levels over a period 
of hours for the identification of reperfusion or complicating 
reocclusion after thrombolytic therapy (Mortara Instruments, 
Inc.). This technique has proved to be equally useful after 
angioplasty (37). Similar work (38,39) in progress at the 
Karolinska Institute in Sweden and elsewhere has compared 
on-line computerized vectorcardiographic monitoring of myo- 
cardial ischemia during both thrombolytic therapy and angio- 
plasty for acute myocardial infarction and other ischemic 
states. Claims that the vectorcardiographic approach is supe- 
rior for establishing infarct-related artery patency have been 
made (40) utilizing instrumentation that has recently become 
available in the United States (Mida CoroNet, Ortivus Medical 
AB, Tfiby, Sweden). The technologies used in the manufacture 
of these dynamic, multilead ECG surveillance systems are 
advanced and somewhat complex because analog signals are 
digitized and computer processed. Accordingly, the cost of 
these systems is considerable; for example, a state-of-the-art 
domestic system costs -$7,500 (exclusive of central processing 
hardware). 
Present study. In this issue of the Journal, Fernandez et al. 
(41) report their experience using Holter monitoring of a 
single lead, reflecting activity in the infarct zone, to assess the 
outcome of reperfusion therapy. An attempt was made to 
assess infarct-related artery patency within 60 min of therapy in 
38 patients, 35 of whom were treated with thrombolytic agents 
and 3 with primary angioplasty. All patients underwent coro- 
nary arteriography of the infarct-related vessel at 60 min; 22 
patients displayed TIMI 2 or 3 flow patency, whereas the 
remaining 16 had persistent occlusion (TIMI 0 or 1 flow). 
Within 10 min of initiating therapy, ST segments were sampled 
at 2.5-, 5-, 10- and 20-min intervals to determine the frequency 
of sampling required for reliable recognition of coronary 
reperfusion. Coronary reperfusion was assessed by the degree 
of resolution of the initial (first recorded) ST segment eleva- 
tion and of the peak (highest) ST segment level measured 
during the first 60 min. The presence of a ->75%, ->50% and 
->25 % decrement from both initial and peak ST segment levels 
was correlated with patency of the infarct-related coronary 
artery at 60 min. Recovery of ST segment shifts ->50% from 
peak levels was found to be the optimal variable for recogniz- 
ing patency at 60 rain, as seen in 21 of the 22 patients with a 
patent vessel compared with only 1 of 16 patients displaying 
persistent occlusion (sensitivity 96%, 95% confidence interval 
[CI] 77% to 99%; specificity 94%, 95% CI 69% to 99%, p < 
0.00001). All 13 patients with TIMI 3 reperfusion flow met this 
criterion. Attesting to the aforementioned unreliability of 
bedside clinical evaluation was the finding that the presence or 
absence of chest pain at 60 min was only 77% sensitive and 
60% specific in predicting angiographic patency. 
As Fernandez et al. (41) acknowledge, there are obvious 
weaknesses to the use of this technique in the dynamic 
identification of infarct-related artery patency. Monitoring of 
the ST segment does not correlate well with late patency, 
notwithstanding its accuracy in assessing early reperfusion. 
Thus, in as little as 90 min after the initiation of therapy, 
sensitivity decreased to 85% from the 60-min sensitivity of 
96%, using a ->50% decline in ST segment elevation. Although 
ST segment monitoring reliably predicted resistance to reper- 
fusion regardless of the sampling interval, the identification of 
patency was best served by the shortest sampling interval 
(2.5 min). 
Fernandez et al. eschew waiting for the achievement of an 
ST segment "steady state" to characterize infarct-related ar- 
tery status, as originally recommended (27). An ST segment 
steady state has been defined as the first 30 consecutive 
minutes during which the ST segment level is equally or less 
deviated than the "final steady state level" measured over a 3- 
to 4-h quiescent period of ST segment monitoring (27). 
Although this criterion of reperfusion within 100 min of 
thrombolytic therapy is highly predictive of infarct-related 
artery patency, Fernandez et al. correctly point to the rewards 
in terms of myocardial salvage of making this determination 
earlier (e.g., 60 min). 
As exciting and potentially useful as the newly reported 
revelations are, and as comparable as these data seem to be 
compared with those obtained by more complex recording 
systems, afew interpretative caveats are in order. 1) At 60 min, 
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identification of the TIMI 2 flow "discomfort zone" (subopti- 
mal flow) is not well served by this technique. 2) The diagnostic 
utility of real-time analysis requires bedside computerized 
recorders to more precisely analyze Holter data, thereby 
adding to cost. 3) Most important, selection of the "right" 
precordial lead configuration to maximize the amplitude of ST 
segment shifts is critical and has not been sufficiently tested in 
this extremely small patient cohort. 
If these issues can be settled with further explorations of 
this more simplified and presumably cost-effective system of 
dynamic ST segment analysis, then we can reasonably expect 
further gains in what has become the new standard of care for 
acute infarction--myocardial reperfusion. The facile and reli- 
able confirmation of reestablished infarct-related artery coro- 
nary blood flow within "the golden hour" of therapeutic 
opportunity will be a clinical victory indeed. 
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